Oncology Institute Inc (TOI)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Oncology Institute Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 5.10 $ — 69% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 23.7%
- Exp. sales growth 3Y > 5% 28.1%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 28.1%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 1
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% –
- ROCE > 15% -38.5%
- Expected return > 10% 21.4%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 25.8% passed
- More than 10% revenue growth is expected for the coming year 24.5% passed
- Share count grows by less than 3% a year 125.4% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 22.3% failed
- Gross margin at 40% or higher and without meaningful erosion 15.2% failed
- Goodwill from acquisitions does not grow faster than revenue 4.4% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 121 m failed
- Return on capital at 15% or higher, or up versus two years ago -38.5% failed
- Insiders hold at least 10% or are net buyers 18.2% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 64.7% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 1
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.14 | -0.18 – -0.09 | 656 | – | 5 |
| 12/31/2027 | -0.03 | -0.12 – 0.14 | 826 | – | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.07 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.13 | – | 100 | 16.90 | -13.10 | 4 | 2 |
| 2025: Q1 | -0.20 | – | 104 | 10.30 | -18.80 | -5 | -5 |
| 2025: Q2 | -0.17 | – | 120 | 21.50 | -14.20 | -10 | -11 |
| 2025: Q3 | -0.17 | – | 137 | 36.70 | -12.10 | -13 | -13 |
| 2025: Q4 | -0.08 | – | 142 | 41.60 | -5.30 | 3 | 2 |
| 2026: Q1 | -0.02 | – | 147 | 41.20 | -1.70 | -2 | -3 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | 113 | 5 | 4 | 0.06 | 6 | – | – |
| 2019 | 155 | -3 | -4 | -0.06 | 4 | 42 | 60 |
| 2020 | 188 | -8 | -14 | -0.24 | 1 | 28 | 66 |
| 2021 | 203 | -46 | -11 | -0.17 | -33 | 104 | 203 |
| 2022 | 252 | -82 | 0 | 0.00 | -62 | 123 | 262 |
| 2023 | 324 | -77 | -83 | -1.13 | -36 | 57 | 209 |
| 2024 | 393 | -60 | -65 | -0.86 | -27 | 4 | 173 |
| 2025 | 503 | -36 | -61 | -0.07 | -25 | -16 | 165 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
The Oncology Institute, Inc., ein onkologisches Unternehmen, bietet verschiedene Onkologiedienstleistungen in den USA an.
| Employees | 641 |
|---|---|
| Headquarters | Cerritos, CA |
| Address | 18000 Studebaker Road, 90703 Cerritos, United States |
| Phone | 562 735 3226 |
| Website | theoncologyinstitute.com |
| IPO Date | 15. Nov 2021 |
| ISIN | US68236X1000 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Daniel Virnich FACHE, M.B.A., M.D. | CEO & Executive Director | 1979 |
| Robert Carter | Chief Financial Officer | 1986 |
| Yale D. Podnos F.A.C.S., M.D., M.P.H. | Chief Medical Officer | 1972 |
| Austin Lee | VP of Accounting & Controller | – |
| Rakesh Panda | Chief Information Officer | – |
| Minh Merchant | Chief Legal Officer | 1973 |
| Nolan Mariano | Chief People Officer | – |
| Mark Hueppelsheuser Esq. | General Counsel | – |
| Jordan McInerney | Chief Development Officer | – |
| Stephen Cella | Senior Vice President of Finance | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 27. Jul 2026 | Kaushal Mohit | Director | Other | 33,133 | 0.00 | – |
| 27. Jul 2026 | McGeorge Anne | Director | Other | 41,165 | 0.00 | – |
| 27. Jul 2026 | Pacala Mark L | Director | Other | 30,120 | 0.00 | – |
| 27. Jul 2026 | Stolper Mark | Director | Other | 31,124 | 0.00 | – |
| 27. Jul 2026 | Tzoumakas Kimberly Jo | Director | Other | 29,116 | 0.00 | – |
| 27. Jul 2026 | Hively Brad | Director | Other | 27,108 | 0.00 | – |
| 27. Jul 2026 | Johnson Karen Marie | Director | Other | 31,124 | 0.00 | – |
| 21. Jul 2026 | Chernett Jorey | 10% Owner | Buy | 18,000 | 5.27 | 94,860 |
| 14. Jul 2026 | Podnos Yale | Chief Medical Officer | Sell | 5,478 | 6.35 | 34,785 |
| 14. Jul 2026 | Podnos Yale | Chief Medical Officer | Other | 5,478 | 2.00 | 10,956 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.